Claims
- 1. A method for treating diabetes in a mammal afflicted therewith comprising administering to said mammal an anti-diabetic effective amount of a compound of the formula:
- 2. The method according to claim 1 wherein R16 is hydrogen.
- 3. The method according to claim 1 wherein OR16 is in the β-imposition.
- 4. The method according to claim 1 wherein R5 and R6 are hydrogen.
- 5. The method according to claim 1 wherein R5 and R6 are hydrogen and at most four of R1, R2, R3, R4, R5, R7, R8, R9, R10, R11, R12, R13 and R16 are other than hydrogen.
- 6. The method according to claim 1 wherein R15 is hydrogen, hydroxy or methoxy.
- 7. The method according to claim 1 in which the compound is administered buccally.
- 8. The method according to claim 1 wherein the compound has the formula:
- 9. The method according to claim 8 wherein R11 and R12 are hydrogen.
- 10. The method according to claim 8 wherein R16 is hydrogen.
- 11. The method according to claim 9 wherein R16 is hydrogen.
- 12. The method according to claim 8 wherein the compound is administered buccally.
- 13. The method according to claim 1 wherein the compound has the formula:
- 14. The method according to claim 13 wherein R11 and R12 are hydrogen.
- 15. The method according to claim 13 wherein R15 is hydrogen or hydroxy.
- 16. The method according to claim 13 wherein R15 is hydrogen or hydroxy, R11 and R12 are hydrogen and R16 is hydrogen.
- 17. The method according to claim 13 wherein R16 is hydrogen.
- 18. The method according to claim 13 wherein the compound is administered buccally.
- 19. The method for treating or preventing hypercholesterolemia in a mammal which method comprises administering to a mammal an anti-hypercholesterolemic effective amount of a compound of the formula
- 20. A method of treating or preventing maladies or diseases resulting from a concentration of glucocorticoids in the plasma of a mammal that is greater than normal, said method comprising administering to said mammal, a therapeutic effective amount. of a compound of the formula:
- 21. A method of reducing the glucocorticoid concentration in the plasma of a mammal comprising administering to said mammal a therapeutically effective amount of a compound of the formula:
- 22. The method according to any one of claims 19-21 wherein R16 is hydrogen.
- 23. The method according to claim 19, 20 or 21 wherein OR16 is in the β-position.
- 24. The method according to claim 19, 20 or 21 wherein R15 is hydrogen, hydroxy or methoxy.
- 25. The method according to claim 19, 20 or 21 wherein the compound is administered buccally.
- 26. The method according to claim 19, 20 or 21 wherein the compound has the formula:
- 27. The method according to claim 26 wherein R11 and R12 are hydrogen.
- 28. The method according to claim 26 wherein R16 is hydrogen.
- 29. The method according to claim 26 wherein the compound is administered buccally.
- 30. The method according to claim 19, 20 or 21 wherein the compound is of the formula:
- 31. The method according to claim 30 wherein R11 and R12 are hydrogen.
- 32. The method according to claim 30 wherein R16 is hydrogen.
- 33. The method according to claim 31 wherein R16 is hydrogen.
- 34. The method according to claim 30 wherein R15 is hydrogen or hydroxy.
- 35. The method according to claim 31 wherein R15 is hydrogen or hydroxy.
- 36. The method according to claim 32 wherein R15 is hydrogen or hydroxy.
- 37. The method according to claim 30 wherein R15 is hydrogen or hydroxy, and R11, R12 and R16 are hydrogen.
- 38. The method according to claim 30 wherein the compound is administered buccally.
- 39. The method according to any one of claims 1, 19, 20 or 21 wherein a statin is additionally present.
- 40. A compound of the formula:
- 41. The compound according to claim 40 wherein R16 is hydrogen.
- 42. The compound according to claim 40 wherein OR16 is in the β-deposition.
- 43. The compound according to claim 40 wherein R5 and R6 are hydrogen.
- 44. The compound according to claim 40 wherein R15 is hydrogen, hydroxy or methoxy.
- 45. The compound according to claim 40 wherein the compound has the formula:
- 46. The compound according to claim 45 wherein R11 and R12 are hydrogen.
- 47. The compound according to claim 45 wherein R15 is hydrogen or hydroxy.
- 48. The compound according to claim 46 wherein R15 is hydrogen or hydroxy.
- 49. The compound according to claim 40 which is 16α-fluoro-7β-hydroxy-5α-androstan-17-one.
- 50. The compound according to claim 40 which is 16α-fluoro-7α-hydroxy-5α-androstan-17-one or 16α-fluoro-5α, 7β-dihydroxy-androstan-17-one, or 16α-fluoro-5α, 7α-dihydroxyandrostan-17-one.
- 51. The method according to any one of claims 1, 19, 20 or 21 wherein the compound is 16α-fluoro-7β-hydroxy-5-androsten-17-one.
- 52. The method according to any one of claims 1, 19, 20 or 21 wherein the compound is 16α-fluoro-7α-hydroxy-5-androsten-17-one, 16α-fluoro-7β-hydroxy-5α-androstan-17-one, 16α-fluoro-7α-hydroxy-5α-androstan-17-one, 16α-fluoro-5α,7α-dihydroxyandrostan-17-one or 16α-fluoro-5α, 7β-dihydroxyandrostan-17-one.
- 53. The compound according to claim 45 wherein R16 is hydrogen.
- 54. The compound according to claim 46 wherein R16 is hydrogen.
- 55. The compound according to claim 47 wherein R16 is hydrogen.
- 56. The compound according to claim 48 wherein R16 is hydrogen.
CROSS REFERENCE TO RELATED APPLICATION
[0001] This application is claiming priority of U.S. Provisional Application No. 60/377,182 filed on May 1, 2002.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60377182 |
May 2002 |
US |